Table 2.

Clinical characteristics of patients in the phase II clinical trial (N = 42; n = 40 treated)

Median age67 y (range, 46–77)
Gender22 females (52%), 20 males (48%)
Race42 white non-Hispanic (100%)
Disease stage42 stage IV (100%)
28 adenocarcinomas (67%)
5 bronchioloalveolar type (12%)
2 squamous cell carcinomas (5%)
10 non–small cell carcinomas not otherwise specified (24%)
Tumor histology1 mixed histology (2%)
1 non–small cell carcinoma with sarcomatoid features (2%)
Prior anti-EGFR therapy9 (21%)
Prior chemotherapies2 (median; range, 0–5)
Smoking status7 never (17%), 6 current (14%), 29 former (69%)